Hetrombopag Olamine

Hetrombopag is Hengrui's oral thrombopoietin receptor agonist - already approved in China for chronic immune thrombocytopenia (ITP) and severe aplastic anemia - now in a Phase 2 study (NCT06433830) for thrombocytopenia caused by concurrent chemoradiotherapy in advanced solid tumor patients [1]. The trial is being run by Sir Run Run Shaw Hospital in collaboration with Jiangsu Hengrui Pharmaceuticals. Commercially, this is a supportive care label expansion, fighting for the same patients that eltrombopag (Novartis Promacta/Revolade - ~$2.2B in global sales in 2023, the franchise peak) and romiplostim (Amgen Nplate) already cover in the US and EU [9]. The bigger lever for ex-China value is Hengrui's separately registered Phase 3 trial (NCT07286032) in chemotherapy-induced thrombocytopenia, sponsored by Hengrui and registered as a placebo-controlled Phase 3 with primary completion in December 2028 [2]. The Phase 2 in chemoradiotherapy-induced thrombocytopenia reads as supportive evidence in an adjacent setting, not a standalone catalyst.

Hetrombopag is not a novel compound. Hengrui has approval in China (since 2021) for chronic ITP and for severe aplastic anemia, and the Phase 3 aplastic anemia trial (NCT03825744) reported at ASH 2024 a complete response rate of 28.1% at 6 months for hetrombopag plus standard immunosuppressive therapy (IST) versus 13.8% for placebo plus IST (between-group difference 14.4%, 95% CI 4.1-24.6, p=0.0129), with overall response 63.8% vs 42.5% and faster median time to first response (87 vs 141 days) [3][8]. An extension study (NCT04961710) is ongoing for long-term safety and durability [4]. For the chemoradiotherapy-induced thrombocytopenia indication, NCT06433830 is a Phase 2 study; no FDA designations have been granted for any hetrombopag indication. Hengrui has separately registered a Phase 3 placebo-controlled trial (NCT07286032) in chemotherapy-induced thrombocytopenia with an estimated start of February 2026 and primary completion December 2028 [2]. That is the trial that will matter most for any FDA submission and global commercial value, not the CRT Phase 2. The original draft's specifics about NCT07286032 enrollment size and a dedicated non-Asian PK arm could not be independently verified from public sources and have been removed pending registry confirmation. A completed Phase 2 in chemotherapy-induced thrombocytopenia in advanced solid tumors (Qin et al., Therapeutic Advances in Medical Oncology, 2024) supports the CIT mechanism story [10]. No public timeline for the NCT06433830 readout has been disclosed, and Hengrui has not announced an FDA filing date for any thrombocytopenia indication. The fact that the CRT trial is hospital-sponsored rather than Hengrui-sponsored is itself a signal about the commercial weight Hengrui places on it.

Platelets are made in the bone marrow by giant cells called megakaryocytes. The body controls platelet output through thrombopoietin (TPO), a hormone made mostly by the liver that binds a receptor called MPL (also written c-Mpl) sitting on the surface of megakaryocytes. When TPO binds, the receptor switches on internal signaling and tells megakaryocytes to mature and release platelets into the bloodstream. Chemotherapy and radiation kill these precursor cells, which is why cancer patients drop platelet counts days to weeks after treatment and sometimes have to delay or cut their chemo dose. Hetrombopag is an oral small molecule that binds MPL and mimics TPO, pushing surviving megakaryocytes to keep producing platelets [7]. Importantly, the approved oral small-molecule class (eltrombopag and, by analogy based on shared chemotype, hetrombopag) binds the transmembrane domain of MPL - a site distinct from where native TPO binds extracellularly - which is why these agents remain active even when endogenous TPO is already elevated, as in aplastic anemia [11]. This mechanism is among the best clinically validated in hematology. Eltrombopag (Novartis Promacta/Revolade) and avatrombopag (Sobi Doptelet) are oral small molecules hitting the same receptor and are both approved in the US. Romiplostim (Amgen Nplate) is an injectable peptide hitting the same receptor through a different binding interface. All three are profitable, commercially established products with multi-year track records in ITP and aplastic anemia. The target itself is not the question. The open question is whether hetrombopag's profile and a likely lower price point can take share from entrenched Western brands once eltrombopag goes off-patent.

NCT06433830 is a Phase 2 study sponsored by Sir Run Run Shaw Hospital in collaboration with Hengrui, enrolling patients with advanced solid tumors receiving concurrent chemoradiotherapy [1]. The trial tests whether hetrombopag can prevent or shorten chemotherapy-induced thrombocytopenia (CIT) - the drop in platelet counts after cytotoxic therapy - that often forces clinicians to reduce, delay, or stop chemo. Grade 3 thrombocytopenia means a platelet count below 50,000 per microliter, low enough that uncontrolled bleeding becomes a real risk; grade 4 is below 25,000, the threshold where most oncologists hold chemotherapy entirely. Specific enrollment numbers, randomization scheme, and a confirmed comparator arm have not been publicly disclosed in the registry detail available. Based on similar CIT and CRT studies, the design is most likely placebo-controlled with platelet count nadir, duration of grade 3 or worse thrombocytopenia, and ability to deliver planned chemo dose intensity as the operative endpoints. This is a single-academic-sponsor investigator-initiated study, which is a weaker package than a multi-site company-run registrational trial. For Western regulatory purposes the more important read is Hengrui's own Phase 3 NCT07286032, which is registered as a placebo-controlled Phase 3 in chemotherapy-induced thrombocytopenia with primary completion December 2028 [2]. An earlier draft asserted a dedicated non-Asian pharmacokinetic (PK) comparison arm - meaning a head-to-head comparison of how the drug is absorbed and cleared in non-Asian versus Asian patients, the kind of dataset the FDA typically wants before accepting a Chinese-origin key package - but that endpoint structure could not be independently verified from public sources and the claim has been removed pending registry confirmation. Either way, NCT06433830 should be read as supportive evidence in a related but distinct setting (radiation plus chemo, not chemo alone), not as the regulatory swing.

The model gives this drug a 6% chance of eventually being approved. That figure starts from the historical rate for Phase 2 drugs in this area, which is about 13%, then adjusts based on ten facts about the trial and its sponsor. Two things push the estimate up: a non-randomized design and open-label blinding. Two things pull it down: the sponsor's weak approval record and limited earlier-phase results. The remaining factors fall close to average for this stage, so they leave the number roughly where the base rate set it.

Efficacy risk lives in the endpoint. TPO agonists reliably raise platelet counts in CIT and CRT settings, which is not in doubt. The question regulators and oncologists actually ask is whether higher platelets translate into fewer chemo dose reductions and better cancer outcomes. Romiplostim has CIT data showing platelet recovery, yet uptake has been modest because oncologists have other ways to manage low platelets (dose hold, switch regimens, transfusion). Hetrombopag has to clear that same bar. Safety risk: eltrombopag carries hepatotoxicity warnings, and the class has questions around thrombosis and bone marrow fibrosis with chronic dosing. Hetrombopag has shown a generally clean profile in Chinese trials but long-term safety data in solid tumor patients receiving cytotoxic therapy is thin. Pharmacokinetics are food-sensitive - fasting duration significantly changes exposure - which is a real-world adherence issue in cancer patients with appetite and GI problems [6]. Execution risk: NCT06433830 is hospital-sponsored, which usually means slower enrollment and weaker monitoring than a Hengrui-run trial. Commercial risk: eltrombopag's core composition-of-matter patent (US 7,598,257) expired December 2024, but remaining Orange Book patents and exclusivities are expected to delay US generic entry until approximately February 2028 [12]. An ANDA generic (Annora Pharma) was already FDA-approved in April 2024 but cannot launch until those exclusivities clear. Hengrui would need to file and receive FDA approval before that ~2028 window closes to compete in the branded market. Hengrui will need a meaningful differentiation story (dosing, food effect, price) to win share, and the Chinese-origin trial package may still need supplementation for FDA.

Watch, do not act on the CRT Phase 2 itself. NCT06433830 is a small hospital-led study in a niche supportive care setting, useful for clinical practice in China and not a stock-moving event. The signal that matters is the Phase 3 NCT07286032 - Hengrui-sponsored, registered with primary completion December 2028 [2]. To size the prize: eltrombopag (Promacta/Revolade) generated approximately $2.2 billion in global sales for Novartis in 2023, its franchise peak, before generic erosion began compressing 2024 figures [9]. Even capturing a single-digit percentage of that pool in CIT/CRT alone would be a $100-300M opportunity for a branded entrant; bigger if hetrombopag also threads ITP and aplastic anemia approvals. If the Phase 3 hits both the platelet endpoint and shows non-inferiority on chemo dose intensity, Hengrui suddenly has a credible global supportive-care asset positioned against an aging eltrombopag franchise heading into 2028 generic entry. Hengrui itself is the larger story. The company has been pushing aggressively into US-readable trials across oncology and supportive care, and several of its assets have been out-licensed to Western developers. A US filing for hetrombopag would be another proof point that Hengrui is becoming a serious global player rather than a domestic-only Chinese pharma. Check back when NCT07286032 begins recruitment, when Hengrui announces an FDA pre-submission meeting on any thrombocytopenia indication, or if a Western partnership is signed for hetrombopag. The closer-term read worth tracking is the Phase 3 aplastic anemia extension NCT04961710 for safety and durability of response - that data will season the broader hetrombopag safety story regardless of which indication files first [4].